Support: 888-992-3836 Home NewsWire Subscriptions
InvestorsHub Logo
Login/Register
RGBP
Regen BioPharma Inc
1,087
Follow
1,087
RGBP
Regen BioPharma Inc
1,087
Follow
1,087
Likes Subject
Older
It's just yet another scam company for Koos SidVicious 06/01/23 8:32 PM
Koo's old company Sybleu did finally start trading Big Brother 06/01/23 6:46 PM
Let us simply celebrate Memorial Day, if possible. SmellMyFinger 05/28/23 8:53 PM
What do you think that guy tells people Musical Shares 05/27/23 6:01 PM
I just want to say that Memorial day SidVicious 05/27/23 4:55 PM
The only thing in the billions is the
Bearish
Bearish
 SidVicious 05/25/23 9:39 PM
I am getting my popcorn and soda ready…
Bullish
Bullish
 Fdc4 05/24/23 10:12 PM
Suppression Of Pathological Angiogenesis By Inhibition Of NR2F6 ronrooster 05/24/23 9:57 AM
Patent Granted 23/05/2023 ronrooster 05/24/23 9:55 AM
This is sadly, true. Huggy Bear 05/22/23 7:09 PM
I'm still laughing hard when Koos came out Musical Shares 05/22/23 5:57 PM
After the deadly kiss of the Reverse Split
Bearish
Bearish
 KIRLIAN88 05/19/23 6:34 AM
Who in their right mind, after reading this SanDiegoAlan 05/19/23 3:58 AM
Thanks Here Today. bme 05/17/23 3:34 PM
https://www.otcmarkets.com/stock/RGBP/disclosure Here Today 05/17/23 2:26 PM
That’s what has been reported to be outstanding Here Today 05/17/23 2:25 PM
Below is from the last filing. Are the bme 05/17/23 1:51 PM
The great doctor-philosopher-sociologist and CEO Koos has gone
Bearish
Bearish
 KIRLIAN88 05/17/23 11:21 AM
Remember all of those who told us this
Bearish
Bearish
 SidVicious 05/16/23 11:06 AM
Where is the Duracrap results? SidVicious 05/16/23 8:43 AM
So, what was THAT about, Friday?? carusso 05/15/23 3:54 AM
HAPPY MOTHERS DAY!!! :) Bigfootbud 05/14/23 4:56 PM
I feel like the fake doctor, in
Bearish
Bearish
 KIRLIAN88 05/13/23 6:35 AM
Penny stock marks will fall for any kind Huggy Bear 05/12/23 7:45 PM
His brother is a OB-GYN doctor. Musical Shares 05/12/23 4:08 PM
In truth I tell you that Koos will
Bearish
Bearish
 KIRLIAN88 05/12/23 11:51 AM
How many shares do you think koos has SidVicious 05/12/23 8:57 AM
RGBP PPS has to be at least $40 archilles 05/10/23 12:38 AM
He has stolen from investors millions of dollar archilles 05/10/23 12:26 AM
The guy runs a biotech from his condo. Musical Shares 05/08/23 6:17 PM
They have been saying it is worth billions
Bearish
Bearish
 bigtalan 05/08/23 5:16 PM
As I kept telling the irrational gamblers in
Bearish
Bearish
 SidVicious 05/08/23 3:46 PM
"the IP is worth billions" goodietime 05/07/23 9:51 PM
But we were told that "in koos we
Bearish
Bearish
 SidVicious 05/07/23 6:55 PM
It is legit, what the CEO has done Fdc4 05/07/23 2:17 PM
I recall that but that doesn't fly with SidVicious 05/07/23 8:39 AM
Sid, Dave said that he and the company all the way up green 05/06/23 2:07 PM
Newsytrends.com... sounds legit. SanDiegoAlan 05/06/23 3:42 AM
RGBP in the news: JDCruz 05/05/23 12:51 PM
Today's pps is equivalent to $0.001 before the
Bearish
Bearish
 KIRLIAN88 05/05/23 10:57 AM
Are we not about a month past since
Bearish
Bearish
 SidVicious 05/05/23 10:44 AM
Right or wrong, we investors should band together archilles 05/04/23 11:21 PM
I do agree with you, Sid. I usually BringMeMoney 05/03/23 12:50 PM
There She Blows Rider25 05/02/23 11:34 AM
TO all of the snake oil pumpers, I
Bearish
Bearish
 SidVicious 05/02/23 8:45 AM
It is but on big board tickers reverse
Bearish
Bearish
 Midwestrader 05/01/23 12:48 PM
it is a bad idea 99.9%of the time archilles 04/30/23 11:19 PM
Time already spoke. I even forgot I had
Bearish
Bearish
 Fdc4 04/30/23 6:36 PM
29 year scamming. Huggy Bear 04/29/23 12:08 PM
Did he say that when there were 5B goodietime 04/26/23 5:37 PM
Likes Subject
Older

Older
SidVicious
06/01/23 8:32 PM
Big Brother
06/01/23 6:46 PM
SmellMyFinger
05/28/23 8:53 PM
Musical Shares
05/27/23 6:01 PM
SidVicious
05/27/23 4:55 PM
SidVicious
05/25/23 9:39 PM
Bearish
Fdc4
05/24/23 10:12 PM
Bullish
ronrooster
05/24/23 9:57 AM
ronrooster
05/24/23 9:55 AM
Huggy Bear
05/22/23 7:09 PM
Musical Shares
05/22/23 5:57 PM
KIRLIAN88
05/19/23 6:34 AM
Bearish
SanDiegoAlan
05/19/23 3:58 AM
bme
05/17/23 3:34 PM
Here Today
05/17/23 2:26 PM
Here Today
05/17/23 2:25 PM
bme
05/17/23 1:51 PM
KIRLIAN88
05/17/23 11:21 AM
Bearish
SidVicious
05/16/23 11:06 AM
Bearish
SidVicious
05/16/23 8:43 AM
carusso
05/15/23 3:54 AM
Bigfootbud
05/14/23 4:56 PM
KIRLIAN88
05/13/23 6:35 AM
Bearish
Huggy Bear
05/12/23 7:45 PM
Musical Shares
05/12/23 4:08 PM
KIRLIAN88
05/12/23 11:51 AM
Bearish
SidVicious
05/12/23 8:57 AM
archilles
05/10/23 12:38 AM
archilles
05/10/23 12:26 AM
Musical Shares
05/08/23 6:17 PM
bigtalan
05/08/23 5:16 PM
Bearish
SidVicious
05/08/23 3:46 PM
Bearish
goodietime
05/07/23 9:51 PM
SidVicious
05/07/23 6:55 PM
Bearish
Fdc4
05/07/23 2:17 PM
SidVicious
05/07/23 8:39 AM
all the way up green
05/06/23 2:07 PM
SanDiegoAlan
05/06/23 3:42 AM
JDCruz
05/05/23 12:51 PM
KIRLIAN88
05/05/23 10:57 AM
Bearish
SidVicious
05/05/23 10:44 AM
Bearish
archilles
05/04/23 11:21 PM
BringMeMoney
05/03/23 12:50 PM
Rider25
05/02/23 11:34 AM
SidVicious
05/02/23 8:45 AM
Bearish
Midwestrader
05/01/23 12:48 PM
Bearish
archilles
04/30/23 11:19 PM
Fdc4
04/30/23 6:36 PM
Bearish
Huggy Bear
04/29/23 12:08 PM
goodietime
04/26/23 5:37 PM

Regen BioPharma Inc (RGBP)

Followers
1087
Posters
2194
Posts (Today)
0
Posts (Total)
117996
Created
09/03/14
Type
Free
Moderators Huggy Bear Sat Naam

Picture

Regen BioPharma 
 

 0.000x  Ticker Symbol: RGBP 

Barchart



All other Regen BioPharma News
https://www.regenbiopharmainc.com/company-news.html




 
 

Regen BioPharma, Inc. 4700 Spring Street, Suite 304
La Mesa, CA 91942 U.S.A.

Telephone: (619) 702-1404
Fax: (619) 330-2328




Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).






 

Product Pipeline | Regen BioPharma, Inc.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
    ?Currently in pre-clinical development 
    Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
    Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
    Additional indications include solid tumors, acute leukemia and GVHD
 

HemaXellerate

Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemo, or chronic conditions
    HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
    ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



     

dCellVax 

Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
    Efficacy endpoints at 6 and 12 months
    Establishment of safety will allow for rapid expansion of patient numbers 
    Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 


     

DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
    Silencing using DiffronC induces differentiation of cancer cells 
    Initial indication is treatment of myelodysplastic syndrome 
    Other indications include solid tumors and acute leukemia



     

Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
    Telomere attrition is involved in aging, cancer and genetic mutations 
    We are developing drugs that modulate telomere maintenance 
    In pre-clinical development for indications of solid cancers and acute leukemia



     
 

 

RGBP Corporate Debt as of September 30, 2022 (latest published financials)

Current News

While the Conventry Debt was paid off (no one has ever contested that), plenty of other debt remains.  The latest Quarterly filing, from November 2022, lists the same list of outstanding debt as the 2nd Quarter filing.

Information on debt still in existance is copied below from the most recent financials signed by the CEO:  https://www.otcmarkets.com/filing/html?id=16204739&guid=dGG-kKAgXc3UQth

As of September  30,2022 the Company has the following Notes  (DEBT) Outstanding

On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.
As of September 30, 2022 $100,000 of the principal amount of the Note remains outstanding.

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

According to RGBP, there is also another Note (debt) issued on the same day, for the same amount (not a duplication)

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

March 13, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is February 24, 2020.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

On March 31, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 31, 2020.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

 On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is May 5, 2020.
As of September  30, 2022 $200,000 of the principal amount of the Note remains outstanding.

On June 26, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $150,000 for consideration consisting of $150,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is June 16, 2020. 
As of September  30, 2022 $150,000 of the principal amount of the Note remains outstanding.

On September 25, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is September 25, 2020.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

On October 3, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 3, 2020
As of September  30, 2022, $50,000 of the principal amount of the Note remains outstanding.


On October 16, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 9, 2020. 
As of September  30, 2022 $100,000 of the principal amount of the Note remains outstanding.

On November 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020.
As of September  30, 2022 $25,000 of the principal amount of the Note remains outstanding.

On November 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020. 
As of September  30 2022 $25,000 of the principal amount of the Note remains outstanding.

On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 20, 2020.
As of September 30, 2022 $100,000 of the principal amount of the Note remains outstanding.

On February 28, 2018 (“Issue date”) the Company issued a two Convertible Notes (“Notes”) in the aggregate face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Notes is February 28, 2021. 
As of September  30, 2022 $100,000 of the principal amount of the Notes remains outstanding.

On July 11, 2018 the Company issued a Convertible Note (“Note”) in the face amount of $11,500 to an entity controlled by the Company’s then Chief Financial Officer for consideration consisting of $11,500 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May 4, 2021.
As of September  30, 2022 $11,500 of the principal amount of the Note remains outstanding.

On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date
As of September  30, 2022, 10,000 of the principal amount of the Note remains outstanding.


On July 19, 2019 the Company issued a convertible promissory note in the face amount of $100,000 (“Note”) for consideration consisting of:  $95,000 cash  the payment of $5,000 of legal fees   The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is July 19, 2020

As of September 30, 2022 $1,000 of the principal amount of the Note remains outstanding.






 
On July 19, 2022 Regen Biopharma, Inc. (the “Company”) issued 54,514,492 common shares (“Shares”) to Coventry Enterprises LLC in satisfaction of $180,552 of convertible indebtedness. The principal balance and accrued interest payable remaining on the $1,500,000 promissory note issued to Coventry Enterprises LLC are both $0 as of July 19,2022
 


Lately, there seems to be a lot of gross misunderstanding, with claims that the company has no debt.   This is false, period.  If you see some of the discussion, it only focuses on one debt that was paid.  There is no question that is true, but these same discussions somehow ignore the many other debts.   From the most recent financials filed by the company, this is the list of RGBP's current debt.   



 
 
 
   
 





Share Dilution History
 
 
Date
 Outsanding Shares Reason for Issue
12/31/21 4,564,002,832  
3/28/22   4,580,002,832 Debt and Interest
4/7/22 4,736,002,832 Debt and Interest
5/16/22 4,820,002,832 Debt
7/1/22 4,920,002,832 Debt
7/17/22 4,970,002,832 Debt and Interest
8/1/22 5,024,517,324 Debt
8/4/22 5,031,517,324 EXPENSES
     
     



2022 Updates RGBP FAQ

1)  Q: I've seen claims that RGBP has a product or products currently in Phase 1 or Phase 2 testing.  Is this true?
A:  Not a single document singed by the company, nor a single PR released by the company mentions ANY current FDA approved lab doing any Phase 1 or Phase 2 testing for RGBP.   This will be updated, as soon as either of those are provided!   Note, "clearance" is not testing.
Volume:
Day Range:
Last Trade Time:
Upgrade to Real-Time
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Detailed Quote
RGBP Latest News
More RGBP News
Most Liked Posts
(Last 30 Days)
Big Brother
06/01/23 6:46 PM
1
Musical Shares
05/27/23 6:01 PM
1
View More
New Post